Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDZ-K: Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Feb 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Primary endpoints: Ability to achieve normokalaemia during the Correction Phase at 3 days and Ability to maintain normokalaemia during the Maintenance Phase at 28 days. Started Apr 2019; status: recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03813407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813407.